Platinoid complexes to target monomeric disordered peptides: a forthcoming solution against amyloid diseases?

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Drug Discovery

Background:

• Alzheimer's disease is characterized by the aggregation of amyloid peptides.
• Disordered amyloid peptides are implicated in the disease's etiology.
• Current therapeutic strategies often struggle to prevent early-stage aggregation.

Purpose of the Study:

• To highlight recent findings on platinoid complexes as therapeutic agents for Alzheimer's disease.
• To investigate the relevance of targeting monomeric soluble disordered amyloid peptides.
• To propose a strategy to preclude the deleterious aggregation process.

Main Methods:

• Review of recent studies on platinoid complexes.
• Analysis of the role of monomeric soluble disordered amyloid peptides.
• Inference of therapeutic mechanisms targeting amyloid aggregation.

Main Results:

• Platinoid complexes demonstrate potential as therapeutic agents.
• Targeting monomeric soluble disordered amyloid peptides is a relevant strategy.
• Inhibition of early-stage amyloid aggregation is achievable.

Conclusions:

• Platinoid complexes offer a promising therapeutic avenue for Alzheimer's disease.
• Interfering with amyloid peptide monomeric forms is crucial for preventing aggregation.
• This approach may offer a novel strategy to combat Alzheimer's disease progression.